

MedLife Group Consolidated Budget for FY 2025



MedLife Group | Budget FY 2025 – Consolidated Statement of Income



	Financial year		Variance
	2024	2025	
<i>(RON, unless otherwise stated)</i>	<i>IFRS, audited</i>	<i>Budget</i>	
Revenue from contracts with customers	2,715,574,711	3,100,291,625	14.2%
Other operating revenues	8,850,263	8,578,508	-3.1%
Operating Income	2,724,424,974	3,108,870,133	14.1%
OPERATING EXPENSES	(2,584,016,603)	(2,929,256,876)	13.4%
EBITDA	395,001,092	465,163,443	17.8%
<i>EBITDA margin (%)</i>	<i>14.5%</i>	<i>15.0%</i>	
OPERATING PROFIT	140,408,371	179,613,257	27.9%
<i>OPERATING PROFIT margin (%)</i>	<i>5.2%</i>	<i>5.8%</i>	
FINANCIAL RESULT	(101,339,241)	(111,558,310)	10.1%
NET RESULT	16,752,428	36,333,923	116.9%
<i>NET RESULT margin (%)</i>	<i>0.6%</i>	<i>1.2%</i>	

Substantiation of 2025 Budget

The **Group's** financial performance is affected, was affected in the past and is expected to be affected in the future by a number of factors, such as:

- Global and regional economic conditions, respectively the economic context at national and regional level that may negatively influence the **Group's** activity refer to factors such as: inflation, recession, changes in fiscal and monetary policy, tighter lending, higher interest rates, new or rising tariffs, currency fluctuations, raw material price (electricity, natural gas), etc.
- Geopolitical context that places pressure on overall demand to a certain extent;
- Evolution of the macroeconomic environment and the general health condition of the targeted population which both determine the consumption of private healthcare services;
- The historically reduced level of the State's investments in public healthcare orientates the population's reach towards private medical services;
- Most of the **Group's** turnover relies on private spending and not on State funded medical insurances;
- **Medlife Group** has a strong and balanced business model which facilitates recurrent revenue capture;
- The **Group's** focus is centralized on expansion by both greenfield investments and acquisitions which provides basis for sustainable growth;
- Labor costs and scale efficiencies will impact profitability.

The estimations and assumptions used are based on historical experience and on other factors which are considered to be reasonable under the current conditions, and their results set the base for judgement with regards to future performance which is not easily outlined from other sources.

The management expects the **Group's** performance to improve over time and its financial results to grow, based on the proven increase in demand for the medical services rendered in the Group's facilities. Moreover, an upside effect will translate from the increased performance of the entities acquired during 2023 and 2024 which are headed to align performance to the Group's threshold as well as organically developed projects for which important CAPEX investments were rendered in 2023 and 2024 and which begin to show their effectiveness as the occupancy rate of the new capacities created is increasing.

The Group estimates that:

- it will continue to capitalize on the medical units of the acquired companies in order to organically develop their operations and to align the acquired companies to a profitability level (EBITDA margin) similar to that of the Group;
- it will continue to analyze the potential acquisition of certain medical companies which will determine the expansion of its services in areas where it already has local presence or will allow the Group to expand in new geographical areas; potential acquisitions are not reflected in the 2025 Budget;
- it will capitalize on growth opportunities for the existing units by building up additional business on the same, already existing, fixed costs structure, especially in case of hospitals;
- it will continue to optimize the mix of services rendered in its units based on specific market conditions, thus aiming to increase the revenue and improve the profit margin of each medical unit;
- it will profit from market consolidation, which is particularly favorable to the leaders of the private medical services market, allowing for an accelerated growth of sales and a more intense presence on the regional market and on niche specialties, facilitating to reach economies of scale.

The actual results may differ from the estimations.